Abstract on autophagy decline with ageing: molecular regulation, tissue specificity and proposed therapies
This abstract reports that autophagy, a lysosome-based self-digestion process that clears damaged organelles and altered proteins, declines in ageing tissues and in several age-related disorders; it names molecular contributors and preclinical strategies, but states that no clinical data confirm safety or efficacy. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract states that autophagy is a lysosome-based self-digestion mechanism removing cellular waste such as damaged organelles and altered proteins. [1]
The abstract names dysregulated AMPK and mTOR nutrient sensing, impaired TFEB and FOXO control and reduced lysosomal competence as contributors to lower autophagy. [1]
The abstract says no clinical data confirm safety and efficacy of these autophagy-targeting treatments. [1]
The source at a glance
- Study type / format
- Abstract of a review-style summary of preclinical data
- Population / context
- Ageing tissues and several age-related disorders, as described in the abstract
- Summary based on
- Study abstract
- Original publication
- May 30, 2026
Autophagy as cellular waste removal in ageing
According to the abstract, cell regulation declines during ageing, shown by buildup of damaged organelles and macromolecules and impaired proteostasis. Autophagy is described as a lysosome-based cell self-digestion mechanism that removes cellular waste, including damaged organelles and abnormally altered proteins or protein aggregates. It is said to help maintain normal cellular functioning by regulating the quality of proteins and organelles. The abstract states that ageing tissues and several age-related disorders show dysfunctional autophagy, which it links to the pathogenesis of cardiovascular, neurodegenerative, metabolic, muscular and ocular disorders.
Supporting source [1]
Named molecular contributors to reduced autophagy
The abstract lists molecular contributors to reduced autophagy: dysregulation of nutrient-sensing pathways such as AMPK and mTOR, impaired transcriptional control by TFEB and FOXO, and reduced lysosomal competence. It does not report measurements of these pathways in specific tissues or quantify the decline.
Supporting source [1]
Preclinical strategies and missing clinical data
In several preclinical studies, the abstract says, pharmacological agents restore autophagic flux by inhibiting mTOR or activating AMPK, and polyphenols, caloric restriction and exercise as lifestyle interventions show an effective role in treating several disorders related to ageing. It describes substantial preclinical data on molecular regulation, tissue-specific decline and therapeutic strategies. However, it states that no clinical data are available to confirm the safety and efficacy of these treatments, and that deeper study of autophagic modulation could serve as a basis for clinical interventions. These are preclinical findings, not demonstrated human benefits.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. It reports preclinical data and states that no clinical data confirm safety or efficacy. It gives no sample sizes, study designs, follow-up or effect estimates, and the described associations are not established causes in humans.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Goyal A, Kumari A, Agrawal N, Yadav HN. · europepmc.org · May 30, 2026